Answers are grounded in this paper and cite their sources.
The evolving therapeutic landscape of DR is rapidly expanding our toolkit for the effective and durable treatment of blinding eye disease. However, further research is required to validate the efficacy of novel therapeutics and characterize real world outcomes.
No takes yet. Share an insight, caveat, or question.
Shughoury et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: